Introduction

A handsomely funded startup, billed as Moderna 2.0, ran into behind-the-scenes problems with its scientific data. Stat's Allison D'Angelois joins us to share her reporting on a cautionary tale in biotech. And we'll discuss the boardroom scandal that has roiled a company that was supposed to be entering a new era.